ABSTRACT
Introduction: The outbreak of the novel coronavirus disease (COVID-19), a highly contagious and deadly infection. Aim: To evaluate the epidemiological pattern and spectrum of the covid ocular morbidity and appraise the typical presentation of ocular manifestations in hospitalized covid patients. Methods: A prospective, cross-sectional study was conducted on individuals, who were hospitalized for COVID treatment between May 2021 and June 2021. The Data on patient history, physical exam, thorough ocular examination, laboratory results, and hospital disposition were collected and analyzed. Results: A total of 658 patients were included. Ocular signs and symptoms were noted in 162 (24.62%) patients. 51.6% patients wereof >50 years of age and 54.1% were males. 71.6% of them belonged to urban community.75.3% patients developed ocular discomfort with in acute (<1 week) period of covid infection. The most common ocular abnormality was watering with conjunctival irritation, followed by conjunctival injection and lid swelling. Among the 162 patients, 30 (79.0%) developed ocular involvement prior to day 30 of onset of their COVID symptoms. 56.7% patients relieved from ocular discomfort after treatment. 5.7% patients reported deterioration of visual acuity. 65.8% patients reported ocular discomfort associated with regular oxygen mask wearing. Most significant ocular morbidity was black discoloration of lids and peri ocular skin, lid swelling, and redness and purulent discharge of conjunctivitis needed emergency ophthalmic reference. Conclusion: spectrum of covid sore eyes extends from ocular irritation to mucormycosis and other long-term complications.
ABSTRACT
Aims & Objectives: To study the effect of COVID 19 on different hematological services. Patients/Materials & Methods: This observational study included 18 patients evaluated from June 2020 till September 2020 belonging to various age groups with a WHO defined hematological disease with laboratory-confirmed and symptomatic COVID-19. The primary outcome was mortality and evaluation of COVID-19 severity in different hematological diseases assessed on day 14 and 28. Patient characteristics, type of disease, symptomatology, HRCT findings and baseline qCRP levels were recorded and the need for oxygenation or in vasiveventilation with administration of various drugs and convalescent plasma and its consecutive effect in delay or nonadministration of chemotherapyevaluated. Results: A total of 140 hematology patients were admitted of which 18 patients (12.85%) were COVID-19 positive. 10 cases (55.55%) were of B cell Acutelymphoblasticleukemia (B-ALL), 3(16.66%) of acutemyeloidleukemia (AML) and 1 (5.55%) each of acute promyelocytic leukemia (APL), T cell acute lymphoblastic leukemia (TALL), T-Lymphoblastic lymphoma (T-LBL), Hodgkins lymphomaandaplasticanaemia. Majority of patients had mild COVID-19 infection (72.22%, n = 13), 4 cases (22.22%) were severely affected and 1 moderately affected. There was delay in administration in chemotherapy in 14 cases(77.77%), while 3 patients continued to receive chemotherapy during the viralillness. Survival at day 14 and 28 in B-ALL was 100%, survival in AML on day 14 and day 28 was 66.6%, survivalin T-ALL on day 14 was 100% and 0% on day 28, survivalin APL and T-LBL on day 14 was0%, survivalin Hodgkinslymphomaandaplasticanemia on day 14 and day 28 was 100%. Discussion & Conclusion: The results indicate that 12.85% cases were COVID-19 positive. 72.22% had mild COVID-19 infection and 22.22% had severe COVID-19 infection. The most common affected was B-ALL (55.55%). In 77.77% cases there was delay in administration of chemotherapy.